ProMetic Life Sciences’ (PLI) Outperform Rating Reiterated at Royal Bank Of Canada
ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating reissued by stock analysts at Royal Bank Of Canada in a research note issued on Thursday.
Several other analysts have also commented on PLI. CIBC lowered their price target on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. TD Securities reiterated a “speculative buy” rating and issued a C$4.50 price target on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Finally, Scotiabank reiterated an “outperform” rating and issued a C$5.00 price target on shares of ProMetic Life Sciences in a research report on Thursday, August 25th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. ProMetic Life Sciences currently has an average rating of “Buy” and an average target price of C$4.84.
ProMetic Life Sciences (TSE:PLI) traded down 1.89% during trading on Thursday, hitting $3.11. 520,719 shares of the company’s stock traded hands. ProMetic Life Sciences has a 12-month low of $1.67 and a 12-month high of $3.62. The stock’s market cap is $1.88 billion. The firm’s 50-day moving average price is $2.92 and its 200 day moving average price is $3.01.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.